A carregar...
Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma
Despite markedly improved treatment options for metastatic melanoma, resistance to targeted therapies such as BRAF inhibitors (BRAFi) or BRAFi plus MEK inhibitors (MEKi) remains a major problem. Our aim was to characterize progression on BRAFi therapy and outcome of subsequent treatment. One hundred...
Na minha lista:
| Publicado no: | Cancer Med |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5773979/ https://ncbi.nlm.nih.gov/pubmed/29266761 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.1267 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|